Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetraxetan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.40 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31540736 | 1.00 | HSD17B10 (0.61) | HSD17B10SLC6A9S1PR1GLAALDH1A1 | |
| Hydrochloric Acid SCHEMBL18110099 | 1.00 | HSD17B10 (0.61) | HSD17B10SLC6A9S1PR1GLAALDH1A1 | |
| Tetraxetan SCHEMBL2017956 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| SCHEMBL6848102 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| SCHEMBL3503521 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| Tetraxetan SCHEMBL18018 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| SCHEMBL173508 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| Tetraxetan SCHEMBL2635294 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| SCHEMBL321989 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 | |
| SCHEMBL6744121 | 0.97 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108264491-B | Preparation method of 1,4,7, 10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid | 威智医药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-110198931-B | Preparation method of 1,4,7, 10-tetraazacyclododecane-1, 4,7, 10-tetraacetic acid | 威智医药有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11214553-B2 | Method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid | VIWIT PHARMACEUTICAL CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| EP-3564218-B1 | METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | VIWIT PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20200347023-A1 | METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | VIWIT PHARMACEU (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3564218-A1 | METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | Viwit Pharmaceutical Co., Ltd. (CN) | 2019-11-06 | — | — | EP | disclosed |
| CN-110198931-A | The preparation method of Cyclen -1,4,7,10- tetraacethyl | 山东威智医药工业有限公司 | 2019-09-03 | — | — | CN | disclosed |
| US-10195295-B2 | Process for purifying 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid | T2PHARMA GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10106489-B2 | Process for the purification of polyaminocarboxylates | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-10-23 | — | — | US | disclosed |
| EP-3102566-B1 | PROCESS FOR PURIFYING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | T2PHARMA GMBH (DE) | 2018-09-12 | — | — | EP | disclosed |
| EP-2948449-B1 | PROCESS FOR PRODUCING 1, 4, 7, 10-TETRAAZACYCLODODECANE-1, 4, 7, 10-TETRAACETIC ACID AND COMPLEXES THEREOF | AGFA HEALTHCARE (BE) | 2016-12-21 | — | — | EP | disclosed |
| EP-3102566-A1 | PROCESS FOR PURIFYING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | AGFA Healthcare (BE) | 2016-12-14 | — | — | EP | disclosed |
| US-9458117-B2 | Process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and complexes thereof | AGFA HEALTHCARE NV (BE) | 2016-10-04 | — | — | US | disclosed |
| US-20160024030-A1 | PROCESS FOR PRODUCING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID AND COMPLEXES THEREOF | AGFA HEALTHCARE (BE) | 2016-01-28 | — | — | US | disclosed |
| EP-2948449-A1 | PROCESS FOR PRODUCING 1, 4, 7, 10-TETRAAZACYCLODODECANE-1, 4, 7, 10-TETRAACETIC ACID AND COMPLEXES THEREOF | AGFA Healthcare (BE) | 2015-12-02 | — | — | EP | disclosed |
| WO-2015117911-A1 | PROCESS FOR PURIFYING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | AGFA HEALTHCARE (BE) | 2015-08-13 | — | — | WO | disclosed |
| US-20140323719-A1 | PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2014-10-30 | — | — | US | disclosed |
| EP-2782900-A2 | PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014114664-A1 | PROCESS FOR PRODUCING 1, 4, 7, 10-TETRAAZACYCLODODECANE-1, 4, 7, 10-TETRAACETIC ACID AND COMPLEXES THEREOF | AGFA HEALTHCARE (BE) | 2014-07-31 | — | — | WO | disclosed |
| WO-2013076743-A2 | PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106489-B2 | Process for the purification of polyaminocarboxylates | SSTR3, TAC3, PDE3A | S1PR1 1977/4885GLA 2613/4885GAA 333/4885 |
| US-11214553-B2 | Method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid | SLC7A1, RCC2, RCC1 | S1PR1 2375/4885GLA 3921/4885GAA 488/4885 |
| US-20200347023-A1 | METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | SLC7A1, RCC2, RCC1 | S1PR1 2375/4885GLA 3921/4885GAA 488/4885 |
| US-20140323719-A1 | PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES | SSTR3, TAC3, PDE3A | S1PR1 1977/4885GLA 2613/4885GAA 333/4885 |
| US-10195295-B2 | Process for purifying 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid | CA7, CA1, ANO1 | S1PR1 1043/4885GLA 550/4885GAA 1097/4885 |
| US-20160024030-A1 | PROCESS FOR PRODUCING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID AND COMPLEXES THEREOF | TCP1, RCC1, CA7 | S1PR1 1342/4885GLA 1456/4885GAA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.